<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of cytomegalovirus infections in children
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of cytomegalovirus infections in children
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of cytomegalovirus infections in children
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gail J Demmler-Harrison, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carrie Armsby, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cytomegalovirus (CMV) is a ubiquitous virus that commonly infects people of all ages throughout the world. In children, the spectrum of disease caused by CMV infection ranges from asymptomatic or mild disease in immunologically normal hosts to severe and potentially life-threatening disease in newborns and immunocompromised children (
         <a class="graphic graphic_table graphicRef101802" href="/z/d/graphic/101802.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Postnatally acquired CMV infection in infants, children, and adolescents will be reviewed here. Congenital CMV infection is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14430.html" rel="external">
          "Congenital cytomegalovirus infection: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/98188.html" rel="external">
          "Congenital cytomegalovirus infection: Management and outcome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          VIROLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         CMV is a member of the Herpesvirus family, along with Epstein-Barr virus; herpes simplex viruses 1 and 2; varicella-zoster virus; and human herpesviruses 6, 7, and 8. These viruses all share properties, including a genome of double-stranded linear DNA, a virus capsid of icosahedral symmetry, and a viral envelope [
         <a href="#rid2">
          2
         </a>
         ]. They also share the biologic properties of latency and reactivation, which cause recurrent infections in the host.
        </p>
        <p>
         CMV replicates slowly, often taking as long as 24 hours to produce virus progeny in infected cells and several days to weeks to produce visible cytopathic effect in laboratory cell lines (
         <a class="graphic graphic_picture graphicRef81737" href="/z/d/graphic/81737.html" rel="external">
          picture 1
         </a>
         ). No distinct serotypes of CMV exist; however, strain differences can be detected by molecular analysis of DNA, providing a classification of genotypes [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4085004119">
         <span class="h1">
          MODES OF TRANSMISSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         CMV can be transmitted by:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          In utero infection
         </strong>
         – Vertical transmission from mother to fetus during pregnancy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4810.html" rel="external">
          "Cytomegalovirus infection in pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Perinatal infection
         </strong>
         – Transmission can occur from contact with maternal cervicovaginal secretions during delivery. (See
         <a class="medical medical_review" href="/z/d/html/4810.html" rel="external">
          "Cytomegalovirus infection in pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Breast milk
         </strong>
         – CMV can be acquired postnatally from breast milk. As discussed below, preterm infants appear to be at greatest risk of having symptomatic infection from early postnatal CMV infection through breast milk. (See
         <a class="local">
          'Early postnatal infection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Close contact
         </strong>
         – CMV can be transmitted among family members; a young child most frequently is the index case. CMV infection during pregnancy most often occurs from maternal exposure to saliva or urine from an infected toddler in the household, especially if the child attends a group childcare setting on a regular basis [
         <a href="#rid4">
          4
         </a>
         ]. Transmission can occur between siblings, from child to parent, and between parents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sexual transmission
         </strong>
         – The sexual transmission of CMV also is well documented with shedding of the virus in cervicovaginal secretions and semen. CMV antibody is associated with other indices of sexual activity, such as a history of sexually transmitted disease, and CMV primary infection has been observed in young women with a recent first sexual experience [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blood transfusion and organ transplantation
         </strong>
         – Blood products and organ transplantation are sources of CMV infection in hospitals. Post-perfusion syndrome caused by CMV can be seen in newborns, especially preterm infants, as well as in infants, older children, and adolescents. Immunosuppressed patients, particularly those with HIV infection, cancer, or receipt of a solid organ or bone marrow transplant, are commonly infected with CMV and are at risk for developing serious disease [
         <a href="#rid1">
          1,6
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Nosocomial transmission of CMV from person to person has not been documented. Universal precautions appear adequate to prevent transmission of CMV within hospitals, and isolation of patients known to be CMV-infected is not routinely recommended [
         <a href="#rid6">
          6
         </a>
         ]. Pregnant health care workers and those contemplating pregnancy are not restricted from caring for CMV-infected patients and should follow universal precautions.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infection with CMV occurs commonly; seroepidemiologic studies have shown the prevalence of antibody to CMV is influenced by age, geography, cultural and socioeconomic status, and child-rearing practices. In developing countries, most children are infected by three years of age, whereas in developed countries, such as the United States or the United Kingdom, infection occurs throughout childhood and adolescence, with as many as 60 to 80 percent of the population infected with CMV by adulthood [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3568427980">
         <span class="h2">
          Congenital infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The epidemiology of congenital CMV infection and CMV infection in pregnancy are discussed in separate topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/14430.html" rel="external">
          "Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Epidemiology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4810.html" rel="external">
          "Cytomegalovirus infection in pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Early postnatal infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Perinatal and early postnatal infection can arise from any of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Via contact with maternal cervicovaginal secretions during delivery (see
         <a class="medical medical_review" href="/z/d/html/4810.html" rel="external">
          "Cytomegalovirus infection in pregnancy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         From breast milk ingestion after delivery – This is a common mode of CMV transmission from mother to infant. Preterm infants appear to be at greatest risk [
         <a href="#rid7">
          7-13
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         From blood transfusions – Transfusion-related postnatal CMV transmission can be prevented by using CMV-seronegative and leukocyte-reduced blood products [
         <a href="#rid11">
          11
         </a>
         ] (see
         <a class="local">
          'Prevention'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         The risk of symptomatic and severe neonatal CMV infection is greatest in the following settings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preterm infants
         </strong>
         – Low birth weight and early transmission of virus in the postnatal period are risk factors for acquiring symptomatic disease [
         <a href="#rid9">
          9
         </a>
         ]. CMV infection in very low birth weight (VLBW; birth weight &lt;1500 grams) infants appears to result from reactivation of the virus in the mother. Seropositive mothers who are breastfeeding have a high rate of CMV reactivation (96 percent) [
         <a href="#rid8">
          8
         </a>
         ]. The rate of transmission to the newborn depends upon whether the infant is fed untreated or frozen/thawed breast milk (higher transmission rates occur with untreated breast milk). This was demonstrated in a meta-analysis of 13 studies including 480 VLBW infants, among whom the rate of CMV transmission from breast milk was 15 percent and the rate of symptomatic CMV infection was 7 percent [
         <a href="#rid7">
          7
         </a>
         ]. The rate of transmission was higher in studies of infants fed untreated breast milk compared with studies of infants fed frozen/thawed breast milk (18 versus 10 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a multicenter, prospective study of 539 VLBW infants, the cumulative incidence of postnatal CMV infection at 12 weeks postnatal age was 7 percent [
         <a href="#rid11">
          11
         </a>
         ]. Transmission occurred from CMV-positive breast milk in nearly all (96 percent) of the cases in this cohort, and there were no transfusion-related infections. Five of the 29 (17 percent) CMV-infected infants developed symptomatic CMV disease, and three infants (10 percent) died.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary immunodeficiency
         </strong>
         – Infants with a primary immune disorder of cellular function (eg, severe combined immune deficiency, natural killer [NK] cell disorders; acquired immune disorders such as HIV) may also manifest severe or fatal postnatally acquired CMV infection [
         <a href="#rid14">
          14,15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">
          "Severe combined immunodeficiency (SCID): An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3949.html" rel="external">
          "NK cell deficiency syndromes: Clinical manifestations and diagnosis", section on 'Introduction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Out-of-home childcare
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children not congenitally or perinatally infected with CMV may acquire the virus during the toddler years or preschool years, especially if they are in contact with other children in a group childcare setting. The prevalence of active CMV shedding in the saliva and urine in children in out-of-home childcare in the United States ranges from 10 to &gt;80 percent [
         <a href="#rid16">
          16
         </a>
         ]. This high prevalence, coupled with the active and often less-than-hygienic daily practices of toddlers, frequently results in horizontal transmission of the virus to both children and adult daycare center workers [
         <a href="#rid17">
          17
         </a>
         ]. Toddlers who are actively shedding CMV may also transmit the virus to their mothers and family members.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Adolescence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adolescence is another period of rapid acquisition of CMV. CMV infection can be acquired through kissing and sexual activity. Congenital CMV infection can occur in infants born to teenage mothers [
         <a href="#rid18">
          18,19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4810.html" rel="external">
          "Cytomegalovirus infection in pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14430.html" rel="external">
          "Congenital cytomegalovirus infection: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations of CMV infection in infants and children depend upon the age and immune status of the patient (
         <a class="graphic graphic_table graphicRef101802" href="/z/d/graphic/101802.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2434772599">
         <span class="h2">
          Congenital infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical manifestations of congenital CMV infection are summarized in the table and are discussed in greater detail separately (
         <a class="graphic graphic_table graphicRef101802" href="/z/d/graphic/101802.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/14430.html" rel="external">
          "Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Early postnatal infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most infants who are infected perinatally or postnatally are asymptomatic. However, preterm infants and those with primary immune disorders are at risk for severe symptomatic infection.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Term infants
         </strong>
         – In term infants, symptoms, when present, are usually transient and include fever, gastrointestinal symptoms (eg, vomiting, diarrhea, abdominal distension), hepatosplenomegaly, hepatitis, mild pneumonitis, and abnormalities of blood counts [
         <a href="#rid20">
          20
         </a>
         ]. Most patients with liver involvement have improvement in liver function tests by two to three months [
         <a href="#rid20">
          20
         </a>
         ]. However, some affected patients may have persistent cholestasis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preterm infants
         </strong>
         – Preterm infants, especially very low birth weight (VLBW; birth weight &lt;1500 grams) infants, are vulnerable to severe CMV disease. Infection may become apparent as early as three weeks and as late as three to six months of age. Early transmission of the virus is a risk factor for symptomatic disease [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In preterm infants, CMV infection may be serious and even fatal if not diagnosed and treated [
         <a href="#rid10">
          10
         </a>
         ]. A sepsis-like syndrome occurs in approximately 15 percent of infected VLBW infants and is associated with hepatosplenomegaly, hepatitis, pneumonitis, and abnormalities of blood counts (including lymphopenia, neutropenia, and/or thrombocytopenia) [
         <a href="#rid7">
          7,21
         </a>
         ]. CMV infection in preterm neonates has also been associated with necrotizing enterocolitis and increased risk of severe retinopathy of prematurity [
         <a href="#rid13">
          13,22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5019.html" rel="external">
          "Neonatal necrotizing enterocolitis: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6263.html" rel="external">
          "Retinopathy of prematurity (ROP): Risk factors, classification, and screening"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is unclear if there are long-term consequences of early postnatal CMV infection in preterm infants. Based on data from follow-up studies comparing CMV-infected infants with noninfected infants matched for gestational age and birth weight, there appear to be no differences in growth, hearing, or cerebral palsy [
         <a href="#rid23">
          23-26
         </a>
         ]. Studies are conflicting as to whether early postnatal CMV infection adversely impacts long-term neurodevelopmental outcomes [
         <a href="#rid23">
          23-27
         </a>
         ] or increases the risk of bronchopulmonary dysplasia [
         <a href="#rid28">
          28,29
         </a>
         ]; if there is an effect, it appears to be small.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a study of 356 preterm infants who were prospectively screened for postnatal CMV infection, infected infants (n = 49) and uninfected infants (n = 307) had similar scores on neurodevelopmental tests performed at 24 to 30 months corrected age [
         <a href="#rid26">
          26
         </a>
         ]. Among children in this cohort who underwent repeat testing at approximately six years of age, mean scores were in the normal range for infected and uninfected children, but infected children had slightly lower verbal intelligence quotient (IQ) scores (96±16 versus 103±15). After adjusting for maternal education status and presence of respiratory distress syndrome, postnatal CMV infection was not independently associated with risk of low verbal IQ. No children with postnatally acquired CMV developed sensorineural hearing loss. In another study of 42 adolescents born very preterm, those with early postnatal CMV infection (n = 19) scored lower than those without (n = 23) for overall IQ (93±15 versus 103±14), though mean scores were in the normal range in both groups [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infants with primary immune disorders
         </strong>
         – Infants with severe combined immune disorder or other primary immune disorders of T cell or natural killer (NK) cell function also may experience severe, even fatal, symptoms associated with postnatally acquired CMV infection [
         <a href="#rid14">
          14,15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">
          "Severe combined immunodeficiency (SCID): An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3949.html" rel="external">
          "NK cell deficiency syndromes: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Immunocompetent children
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acquired CMV infection in healthy children and adolescents is most often asymptomatic. However, approximately 10 percent of acquired CMV infections produce symptoms. CMV can cause a mononucleosis-like syndrome; the most common manifestations are fever, fatigue, pharyngitis, adenopathy (especially cervical adenopathy), and hepatitis [
         <a href="#rid21">
          21
         </a>
         ]. Headache, abdominal pain with diarrhea, arthralgias, and rash also may occur. Laboratory abnormalities can include abnormal lymphocyte count (lymphocytosis or lymphopenia), neutropenia, thrombocytopenia, and elevated transaminases. Unlike mononucleosis caused by Ebstein-Barr virus, the heterophile antibody (Monospot) test is negative in CMV-associated mononucleosis-like illness. (See
         <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">
          "Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults", section on 'CMV mononucleosis'
         </a>
         .)
        </p>
        <p>
         Unusual manifestations or complications of acquired CMV infections in healthy individuals include rare reports of pneumonitis, myopericarditis, hemolytic anemia, viral hemophagocytic syndrome, granulomatous hepatitis, Guillain-Barré syndrome, and meningoencephalitis [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Immunocompromised hosts
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunocompromised children and adolescents are at risk for acquiring serious CMV disease. Infection may result from reactivation of endogenous virus, infection from the transplanted organ, or from blood product transfusion. An imbalance of increased viral activation and lack of immune surveillance commonly produces CMV disease in these patients.
        </p>
        <p>
         Patient populations at risk for CMV disease in this setting include [
         <a href="#rid1">
          1,30
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transplant recipients, especially if any of the following apply:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Donor is CMV-seropositive and recipient is CMV-seronegative
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Donor has CMV viremia or high CMV viral load
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recipient had high pretransplant CMV viral load
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recipient has evidence of decreased T cell function (eg, from the immunosuppressive regimen)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with primary or acquired immune disorders that affect T lymphocytes or NK cells
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with hematologic malignancies (eg, acute lymphocytic and acute myeloid leukemias)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients receiving immunosuppressive therapy for Crohn's disease or ulcerative colitis
        </p>
        <p>
        </p>
        <p>
         The consequences of acquired CMV infections in immunocompromised hosts include significant morbidity and increased risk of mortality.
        </p>
        <p>
         The most common manifestations of CMV infection in immunocompromised children include fever, malaise, and leukopenia. Other signs and symptoms include colitis, retinitis, pneumonitis, and meningoencephalitis. Manifestations in transplant recipients may include (see
         <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">
          "Infection in the solid organ transplant recipient", section on 'CMV and EBV'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hematopoietic stem cell transplant recipients – CMV typically causes fever leukopenia syndrome or pneumonitis in this setting. (See
         <a class="medical medical_review" href="/z/d/html/1403.html" rel="external">
          "Overview of infections following hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal transplant recipients – CMV infection in renal transplant recipients can be associated with graft loss. (See
         <a class="medical medical_review" href="/z/d/html/7300.html" rel="external">
          "Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant patients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver transplant recipients – CMV may cause hepatitis and colitis in liver transplant recipients. (See
         <a class="medical medical_review" href="/z/d/html/4588.html" rel="external">
          "Infectious complications in liver transplantation", section on 'Cytomegalovirus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heart transplant recipients – CMV can cause myocarditis in heart transplant recipients, and it can contribute to allograft vasculopathy. (See
         <a class="medical medical_review" href="/z/d/html/3517.html" rel="external">
          "Heart transplantation in adults: Cardiac allograft vasculopathy pathogenesis and risk factors", section on 'Cytomegalovirus infection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lung transplant recipients – CMV typically causes pneumonitis in lung transplant recipients. (See
         <a class="medical medical_review" href="/z/d/html/15396.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Children with HIV and CMV coinfection may experience retinitis, colitis, pneumonitis, and encephalitis/encephalopathy; a rapid progression of HIV infection frequently occurs during infancy in these patients if they are untreated [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5963.html" rel="external">
          "Pediatric HIV infection: Classification, clinical manifestations, and outcome", section on 'Cytomegalovirus disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          LABORATORY DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The laboratory diagnosis of CMV infection depends upon the specific setting in which CMV disease is under consideration.
        </p>
        <p class="headingAnchor" id="H3030280753">
         <span class="h2">
          Congenital infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory tests for diagnosis of congenital CMV infection are summarized in the table and are discussed in detail separately (
         <a class="graphic graphic_table graphicRef98862" href="/z/d/graphic/98862.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/14430.html" rel="external">
          "Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Diagnostic approach'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H343105">
         <span class="h2">
          Early postnatal infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of perinatal/postnatal CMV infection is confirmed with positive urine CMV testing (with culture or polymerase chain reaction [PCR]) performed after the first three weeks of life, in conjunction with negative testing performed within the first three weeks (thereby excluding congenital CMV infection).
        </p>
        <p>
         Urine is preferred over saliva for detection of postnatal CMV infection because it is more sensitive than saliva [
         <a href="#rid32">
          32
         </a>
         ]. In addition, false positives may occur due to contamination of the saliva sample with retained breast milk in the mouth of the newborn if collected within an hour of breast milk feeding. If a CMV urine or saliva detection test was not performed at birth, retrospective analysis can be performed using a newborn dried blood spot obtained for the purposes of universal newborn screening. (See
         <a class="medical medical_review" href="/z/d/html/14430.html" rel="external">
          "Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Birth to three weeks'
         </a>
         .)
        </p>
        <p>
         At the author's institution, urine CMV testing is performed in preterm infants who present with clinical sepsis if the work-up for bacterial, fungal, and other viral causes (eg, herpes simplex virus) is negative in patients with unexplained thrombocytopenia. (See
         <a class="medical medical_review" href="/z/d/html/88740.html" rel="external">
          "Clinical features and diagnosis of bacterial sepsis in preterm infants &lt;34 weeks gestation", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
         Neonates with severe CMV infection, such as viral sepsis, necrotizing enterocolitis, hepatitis, pneumonitis, or thrombocytopenia are typically viremic, and CMV virus can be detected by CMV quantitative PCR in whole blood or plasma [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         Serology for CMV immunoglobulin G (IgG) antibody determination is
         <strong>
          not
         </strong>
         helpful in diagnosing early postnatal infection, because a positive result may only reflect passive transfer of maternal antibody to the infant.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Children and adolescents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnosis of primary CMV infection in immunocompetent hosts is usually made using serologic studies. The detection of CMV-specific immunoglobulin M (IgM) and/or a fourfold rise in CMV-specific IgG establish a presumptive diagnosis in the appropriate clinical setting. (See
         <a class="medical medical_review" href="/z/d/html/8305.html" rel="external">
          "Approach to the diagnosis of cytomegalovirus infection", section on 'Immunocompetent hosts'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Immunocompromised hosts
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory confirmation that a CMV infection is causing disease in an immunocompromised host is difficult and frequently requires demonstration of CMV in the end organ involved, in combination with a positive or rising quantitative PCR for CMV in the blood. Serology and urine or saliva cultures rarely are helpful in this population because most patients are seropositive and shed virus and the presence of these positive tests is not specific for the development of disease. (See
         <a class="medical medical_review" href="/z/d/html/8305.html" rel="external">
          "Approach to the diagnosis of cytomegalovirus infection", section on 'Immunocompromised hosts'
         </a>
         .)
        </p>
        <p>
         At some centers, transplant recipients are monitored by routine (eg, weekly) laboratory viral surveillance using quantitative whole blood or plasma CMV PCR [
         <a href="#rid33">
          33,34
         </a>
         ]. If the PCR is positive or rising, antiviral therapy is initiated even if overt disease has not yet developed. This strategy, referred to as "preemptive" therapy, is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/16533.html" rel="external">
          "Prevention of viral infections in hematopoietic cell transplant recipients", section on 'CMV prevention'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/105281.html" rel="external">
          "Prevention of cytomegalovirus disease in kidney transplant recipients", section on 'Preemptive therapy (low risk)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H3014247347">
         <span class="h2">
          Congenital infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of congenital CMV infection is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/98188.html" rel="external">
          "Congenital cytomegalovirus infection: Management and outcome", section on 'Antiviral treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1407702561">
         <span class="h2">
          Early postnatal infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most early postnatal infections in term infants are asymptomatic and do not require treatment; however, treatment may be warranted in preterm or very low birth weight (VLBW) infants with severe infection. We treat preterm or VLBW infants who have serious CMV disease with antiviral therapy (
         <a class="drug drug_pediatric" data-topicid="13331" href="/z/d/drug information/13331.html" rel="external">
          ganciclovir
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13002" href="/z/d/drug information/13002.html" rel="external">
          valganciclovir
         </a>
         , depending on whether or not the infant is able to take oral medication). Although clinical trial data are lacking, case series of VLBW infants with serious life-threatening CMV disease have suggested that treatment with antiviral medication is associated with improved survival [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Infants who are able to take oral medication can be treated with oral
         <a class="drug drug_pediatric" data-topicid="13002" href="/z/d/drug information/13002.html" rel="external">
          valganciclovir
         </a>
         (15 to 16 mg/kg/dose every 12 hours). Infants unable to take oral medication are treated with intravenous (IV)
         <a class="drug drug_pediatric" data-topicid="13331" href="/z/d/drug information/13331.html" rel="external">
          ganciclovir
         </a>
         (6 mg/kg/dose every 12 hours) and are transitioned to valganciclovir once they are stable and tolerating oral feeds [
         <a href="#rid21">
          21
         </a>
         ]. The duration of therapy is typically three weeks, though some infants may require longer therapy to resolve end-organ disease and CMV viremia. Consultation with an infectious disease specialist is recommended for these challenging situations.
        </p>
        <p>
         Monitoring during
         <a class="drug drug_pediatric" data-topicid="13331" href="/z/d/drug information/13331.html" rel="external">
          ganciclovir
         </a>
         treatment includes assessment of clinical response and measurement of virologic response with weekly quantitative CMV polymerase chain reaction (PCR). In addition, monitoring for bone marrow and hepatic toxicity includes twice-weekly measurements of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and complete blood count with differential and platelet count.
        </p>
        <p class="headingAnchor" id="H3052101031">
         <span class="h2">
          Immunocompetent children
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antiviral therapy is not usually indicated for CMV infections in immunocompetent children. In these patients, the illness is generally self-limited, with complete recovery over a period of days to weeks. Patients with mononucleosis-like symptoms can generally be managed with supportive care alone (eg, antipyretics, fluids, rest). (See
         <a class="medical medical_review" href="/z/d/html/8318.html" rel="external">
          "Infectious mononucleosis", section on 'Symptomatic treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Immunocompromised hosts
         </span>
         <span class="headingEndMark">
          —
         </span>
         For immunocompromised children with active CMV disease, we recommend antiviral therapy. We also suggest antiviral therapy for immunocompromised children who lack signs or symptoms of end-organ disease but have evidence of CMV viremia (eg, positive or rising quantitative PCR). Serious infections are treated with IV
         <a class="drug drug_pediatric" data-topicid="13331" href="/z/d/drug information/13331.html" rel="external">
          ganciclovir
         </a>
         ; mild CMV disease can be treated with oral
         <a class="drug drug_pediatric" data-topicid="13002" href="/z/d/drug information/13002.html" rel="external">
          valganciclovir
         </a>
         .
        </p>
        <p>
         Our recommendations are based on observational studies demonstrating a substantial risk of morbidity and mortality associated with CMV disease in immunocompromised children [
         <a href="#rid1">
          1,34-39
         </a>
         ], as well as indirect evidence from clinical trials in immunocompromised adult patients (eg, solid organ transplant recipients, HIV-infected patients) [
         <a href="#rid40">
          40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7300.html" rel="external">
          "Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant patients", section on 'Treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3731.html" rel="external">
          "Treatment of AIDS-related cytomegalovirus retinitis", section on 'Systemic therapy'
         </a>
         .)
        </p>
        <p>
         Treatment of CMV disease in immunocompromised pediatric patients is similar to that in adults. Treatment is usually divided into an induction phase and a maintenance phase (also called secondary prophylaxis).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Induction phase – The induction phase consists of
         <a class="drug drug_pediatric" data-topicid="13331" href="/z/d/drug information/13331.html" rel="external">
          ganciclovir
         </a>
         5 mg/kg/dose IV every 12 hours for two to three weeks, depending upon the clinical and virologic response. This is followed by a maintenance phase for high-risk patients (eg, hematopoietic stem cell transplant recipients, patients with HIV infection, or those in whom prolonged immunosuppression is anticipated) [
         <a href="#rid41">
          41,42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintenance therapy – Maintenance therapy usually consists of a single daily dose of
         <a class="drug drug_pediatric" data-topicid="13331" href="/z/d/drug information/13331.html" rel="external">
          ganciclovir
         </a>
         IV at 5 mg/kg administered every other day or five days a week, skipping the weekend. Oral
         <a class="drug drug_pediatric" data-topicid="13002" href="/z/d/drug information/13002.html" rel="external">
          valganciclovir
         </a>
         , at 15 mg/kg/dose every 12 hours, may be used for maintenance therapy in patients who are able to tolerate and absorb oral medication. For transplant recipients with active CMV disease, management may also include reducing immunosuppression. Such decisions should be made by the child's transplant team.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="13331" href="/z/d/drug information/13331.html" rel="external">
          Ganciclovir
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13002" href="/z/d/drug information/13002.html" rel="external">
          valganciclovir
         </a>
         both produce a reversible, dose-dependent bone marrow suppression that may manifest as leukopenia, neutropenia, anemia, or thrombocytopenia. The incidence of neutropenia associated with oral valganciclovir may be lower than with IV ganciclovir. In addition, elevation of liver transaminases may be observed but rarely to the level requiring cessation of the medication. Patients receiving ganciclovir or valganciclovir should have complete blood counts, AST, and ALT monitored regularly. Ganciclovir and valganciclovir are excreted renally, and the dose should be adjusted if renal insufficiency or renal failure is present. Local infiltration of the IV ganciclovir solution also may produce local reaction, ulcers, and even scarring.
        </p>
        <p>
         If clinical or virologic response is not observed within several weeks of treatment with
         <a class="drug drug_pediatric" data-topicid="13331" href="/z/d/drug information/13331.html" rel="external">
          ganciclovir
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13002" href="/z/d/drug information/13002.html" rel="external">
          valganciclovir
         </a>
         , then
         <a class="drug drug_pediatric" data-topicid="13325" href="/z/d/drug information/13325.html" rel="external">
          foscarnet
         </a>
         may be added to the regimen if renal function allows.
         <a class="drug drug_pediatric" data-topicid="13155" href="/z/d/drug information/13155.html" rel="external">
          Cidofovir
         </a>
         is another antiviral with specific anti-CMV activity that may be used in children with careful monitoring of renal function and metabolic condition. Some experts add hyperimmune CMV globulin to the treatment regimen in high-risk patients, but the efficacy of this approach is uncertain. Testing for CMV antiviral resistance may be indicated, especially in immune-compromised patients who fail to respond to treatment with ganciclovir or valganciclovir.
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preventing CMV infection is challenging because the virus is so ubiquitous and infection occurs so commonly. However, in certain circumstances (eg, pregnancy), trying to prevent CMV infection is desirable. The
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Fcmv%2Findex.html&amp;token=mjmpv7xMHRIW2nr%2B3NCnsaVwRe%2FbvYSP3eD7ZV5zBDe%2FUfN6MseIo%2Ff7BJA7dT6L&amp;TOPIC_ID=5965" target="_blank">
          Centers for Disease Control and Prevention
         </a>
         provides additional resources for prevention of CMV infection.
        </p>
        <p class="headingAnchor" id="H4149985770">
         <span class="h2">
          Prevention during pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prevention strategies aimed at reducing the risk of acquisition of primary CMV during pregnancy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4810.html" rel="external">
          "Cytomegalovirus infection in pregnancy", section on 'Behavioral risk reduction interventions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2980404492">
         <span class="h2">
          Prevention of neonatal transmission
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preventive measures to reduce transmission of CMV to newborns include [
         <a href="#rid43">
          43
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of CMV-seronegative or leukocyte-reduced blood for extremely preterm infants, which essentially eliminates the risk of transfusion-related CMV infection [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="local">
          'Blood products and organ donors'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of maternal breast milk by freezing/thawing or pasteurization. Freezing/thawing appears to reduce the risk of transmission but does not eliminate it [
         <a href="#rid9">
          9
         </a>
         ]. Pasteurization may reduce or even prevent transmission of CMV but removes many of the beneficial components. Screening donated breast milk for CMV is important in preventing CMV transmission from this source [
         <a href="#rid44">
          44
         </a>
         ]. Methods to reduce the risk of transmission through human milk are the subject of active research in the attempt to inactivate the virus yet retain the nutritional and immunologic benefits of human milk.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h2">
          Blood products and organ donors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Blood products given to newborns (especially preterm infants), pregnant individuals, and immunocompromised patients should be from CMV-seronegative donors or leukoreduced. Leukoreduction appears to be comparable with CMV seronegative blood in preventing CMV transmission. Selection of CMV-seronegative donors for organ and hematopoietic stem cell transplantation, when appropriate and available, also will reduce the risk of CMV infection and disease in CMV-negative recipients. (See
         <a class="medical medical_review" href="/z/d/html/5935.html" rel="external">
          "Red blood cell transfusion in infants and children: Selection of blood products", section on 'Leukoreduced red blood cells'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h2">
          Prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Passive immunoprophylaxis with intravenous
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         (IVIG) or CMV hyperimmune globulin may prevent acquisition of serious CMV disease in hematopoietic stem cell and solid organ transplant recipients at high risk for acquiring CMV disease [
         <a href="#rid30">
          30,45
         </a>
         ].
        </p>
        <p>
         Antiviral prophylaxis with
         <a class="drug drug_pediatric" data-topicid="13331" href="/z/d/drug information/13331.html" rel="external">
          ganciclovir
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13002" href="/z/d/drug information/13002.html" rel="external">
          valganciclovir
         </a>
         administered pre-transplant and immediately post-transplant to recipients at high risk for CMV disease also may reduce the risk of serious CMV disease in the early post-transplant period. However, CMV infection and disease may still develop or may be delayed. (See
         <a class="medical medical_review" href="/z/d/html/16533.html" rel="external">
          "Prevention of viral infections in hematopoietic cell transplant recipients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/105281.html" rel="external">
          "Prevention of cytomegalovirus disease in kidney transplant recipients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h2">
          Vaccines
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of experimental CMV vaccines have been evaluated in clinical trials; however, none are licensed. Experts are hopeful that a CMV vaccine someday will be available for prevention of CMV disease in newborns and immunocompromised patients [
         <a href="#rid46">
          46-48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4810.html" rel="external">
          "Cytomegalovirus infection in pregnancy", section on 'Development of a vaccine'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H62235051">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/83958.html" rel="external">
          "Patient education: Cytomegalovirus (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H347458443">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Virology and epidemiology
         </strong>
         – Cytomegalovirus (CMV), a member of the Herpesvirus family, is a ubiquitous virus that infects people of all ages throughout the world. Although most CMV infections are asymptomatic or cause mild disease, the virus can cause serious disease in preterm and very low birth weight (VLBW) newborns and immunocompromised children (
         <a class="graphic graphic_table graphicRef101802" href="/z/d/graphic/101802.html" rel="external">
          table 1
         </a>
         ). CMV can be transmitted perinatally from maternal breast milk or cervical vaginal secretions, through contact with toddlers in the childcare setting, among family members and close contacts, between partners through intimate or sexual contact, and through transfusion of blood products or organ transplantation. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Modes of transmission'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14430.html" rel="external">
          "Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acquired CMV in infancy and childhood
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Early postnatal infection
         </strong>
         – Perinatal and early postnatal infection can arise from maternal secretions, ingestion of breast milk, or blood product transfusions. Most early postnatal infections in term infants are asymptomatic or cause a mild illness. In preterm and VLBW infants, CMV can cause a variety of clinical symptoms, most commonly sepsis-like syndrome, pneumonitis, hepatitis, and necrotizing enterocolitis. Preterm infants are at higher risk for developing severe life-threatening disease. (See
         <a class="local">
          'Early postnatal infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immunocompetent children
         </strong>
         – Acquired CMV infection in healthy children and adolescents is most often asymptomatic. Approximately 10 percent of infected children develop a mononucleosis-like illness, including fever, fatigue, pharyngitis, adenopathy (especially cervical adenopathy), and hepatitis. (See
         <a class="local">
          'Immunocompetent children'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immunocompromised hosts
         </strong>
         – Risk factors for CMV infections in immunocompromised hosts include transplantation of an organ from a CMV-seropositive donor into a CMV-seronegative recipient, depressed T cell function, natural killer (NK) cell disorders, and transplantation of a CMV-infected organ. Clinical manifestations of infection in immunocompromised infants, children, and adolescents include fever, leukopenia, and malaise with end-organ involvement (such as kidney graft loss, hepatitis, pneumonitis, or myocarditis). (See
         <a class="local">
          'Immunocompromised hosts'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Laboratory tools for the diagnosis of CMV include virus isolation in culture, detection of CMV DNA using polymerase chain reaction (PCR), and serology. The approach depends on the setting (see
         <a class="local">
          'Laboratory diagnosis'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Congenital CMV infection is discussed separately (see
         <a class="medical medical_review" href="/z/d/html/14430.html" rel="external">
          "Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Approach to testing'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Perinatal and early postnatal CMV infection is diagnosed by isolation or PCR after the first three weeks of life, in conjunction with negative testing performed within the first three weeks (thereby excluding congenital CMV infection) (see
         <a class="local">
          'Early postnatal infection'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In children and adolescents, diagnosis of CMV infection in immunocompetent hosts is usually made using serologic studies (see
         <a class="medical medical_review" href="/z/d/html/8305.html" rel="external">
          "Approach to the diagnosis of cytomegalovirus infection", section on 'Immunocompetent hosts'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In immunocompromised hosts, confirmation of CMV infection is challenging and may require demonstration of infection in blood and an end organ (see
         <a class="medical medical_review" href="/z/d/html/8305.html" rel="external">
          "Approach to the diagnosis of cytomegalovirus infection", section on 'Immunocompromised hosts'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Treatment of acquired CMV infections in infants and children depends on the clinical circumstances (see
         <a class="local">
          'Treatment'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Preterm infants with postnatal infection
         </strong>
         – For preterm or VLBW infants who have serious early postnatal CMV disease (eg, sepsis syndrome, pneumonitis, hepatitis, necrotizing enterocolitis), we suggest antiviral treatment with
         <a class="drug drug_pediatric" data-topicid="13331" href="/z/d/drug information/13331.html" rel="external">
          ganciclovir
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13002" href="/z/d/drug information/13002.html" rel="external">
          valganciclovir
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Early postnatal infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immunocompetent children
         </strong>
         – Antiviral therapy is not usually indicated for CMV infections in immunocompetent children. (See
         <a class="local">
          'Immunocompetent children'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immunocompromised children
         </strong>
         – For immunocompromised children with active CMV disease, we recommend antiviral therapy with
         <a class="drug drug_pediatric" data-topicid="13331" href="/z/d/drug information/13331.html" rel="external">
          ganciclovir
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). We also suggest antiviral therapy with ganciclovir or
         <a class="drug drug_pediatric" data-topicid="13002" href="/z/d/drug information/13002.html" rel="external">
          valganciclovir
         </a>
         for immunocompromised children who lack signs or symptoms of CMV disease but have laboratory evidence of CMV viremia (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Immunocompromised hosts'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – Strategies for preventing CMV infection include personal hygienic precautions and use of CMV-seronegative or leukocyte-reduced blood products for at-risk patients (eg, preterm infants and immunocompromised children). In preterm infants, treatment of maternal breast milk by freezing/thawing or pasteurization may reduce transmission. Use of intravenous
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         (IVIG) or CMV hyperimmune globulin in combination with antiviral drugs can reduce the risk of CMV infection in organ transplant patients. (See
         <a class="local">
          'Prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Harrison GJ. Cytomegalovirus. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 8th ed, Cherry JD, Harrison GJ, Kaplan SL, Steinbach W, Hotez P, et al (Eds), Elsevier Saunders, 2019. p.1429.
         </li>
         <li class="breakAll">
          Mocarski ES. Cytomegaloviruses and their replication. In: Fields Virology, 3rd ed, Fields B, Knipe D, Howley P (Eds), Lippincott-Raven, Philadelphia 1996. Vol 2, p.2447.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker A, Petheram SJ, Ballard L, et al. Characterization of human cytomegalovirus strains by analysis of short tandem repeat polymorphisms. J Clin Microbiol 2001; 39:2219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alain S, Garnier-Geoffroy F, Labrunie A, et al. Cytomegalovirus (CMV) Shedding in French Day-Care Centers: A Nationwide Study of Epidemiology, Risk Factors, Centers' Practices, and Parents' Awareness of CMV. J Pediatric Infect Dis Soc 2020; 9:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demmler GJ. Infectious Diseases Society of America and Centers for Disease Control. Summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis 1991; 13:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demmler GJ, Yow MD, Spector SA, et al. Nosocomial cytomegalovirus infections within two hospitals caring for infants and children. J Infect Dis 1987; 156:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanzieri TM, Dollard SC, Josephson CD, et al. Breast milk-acquired cytomegalovirus infection and disease in VLBW and premature infants. Pediatrics 2013; 131:e1937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamprecht K, Maschmann J, Vochem M, et al. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet 2001; 357:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maschmann J, Hamprecht K, Dietz K, et al. Cytomegalovirus infection of extremely low-birth weight infants via breast milk. Clin Infect Dis 2001; 33:1998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunkel J, Wolfs TF, de Vries LS, Nijman J. Predictors of severity for postnatal cytomegalovirus infection in preterm infants and implications for treatment. Expert Rev Anti Infect Ther 2014; 12:1345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Josephson CD, Caliendo AM, Easley KA, et al. Blood transfusion and breast milk transmission of cytomegalovirus in very low-birth-weight infants: a prospective cohort study. JAMA Pediatr 2014; 168:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehler K, Oberthuer A, Lang-Roth R, Kribs A. High rate of symptomatic cytomegalovirus infection in extremely low gestational age preterm infants of 22-24 weeks' gestation after transmission via breast milk. Neonatology 2014; 105:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martins-Celini FP, Yamamoto AY, Passos DM, et al. Incidence, Risk Factors, and Morbidity of Acquired Postnatal Cytomegalovirus Infection Among Preterm Infants Fed Maternal Milk in a Highly Seropositive Population. Clin Infect Dis 2016; 63:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelty WJ, Beatty SA, Wu S, et al. The role of breast-feeding in cytomegalovirus transmission and hematopoietic stem cell transplant outcomes in infants with severe combined immunodeficiency. J Allergy Clin Immunol Pract 2019; 7:2863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vicetti Miguel CP, Mejias A, Ramilo O, et al. Cytomegalovirus Meningitis in an Infant with Severe Combined Immunodeficiency. J Pediatr 2016; 173:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adler SP. Cytomegalovirus transmission among children in day care, their mothers and caretakers. Pediatr Infect Dis J 1988; 7:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adler SP. Cytomegalovirus and child day care. Evidence for an increased infection rate among day-care workers. N Engl J Med 1989; 321:1290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Istas AS, Demmler GJ, Dobbins JG, Stewart JA. Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. Clin Infect Dis 1995; 20:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler KB, Stagno S, Pass RF. Maternal age and congenital cytomegalovirus infection: screening of two diverse newborn populations, 1980-1990. J Infect Dis 1993; 168:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tezer H, Kanık Yüksek S, Gülhan B, et al. Cytomegalovirus hepatitis in 49 pediatric patients with normal immunity. Turk J Med Sci 2016; 46:1629.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Cytomegalovirus infection. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th, Kimberlin DW (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.317.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tengsupakul S, Birge ND, Bendel CM, et al. Asymptomatic DNAemia heralds CMV-associated NEC: case report, review, and rationale for preemption. Pediatrics 2013; 132:e1428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vollmer B, Seibold-Weiger K, Schmitz-Salue C, et al. Postnatally acquired cytomegalovirus infection via breast milk: effects on hearing and development in preterm infants. Pediatr Infect Dis J 2004; 23:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goelz R, Meisner C, Bevot A, et al. Long-term cognitive and neurological outcome of preterm infants with postnatally acquired CMV infection through breast milk. Arch Dis Child Fetal Neonatal Ed 2013; 98:F430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bevot A, Hamprecht K, Krägeloh-Mann I, et al. Long-term outcome in preterm children with human cytomegalovirus infection transmitted via breast milk. Acta Paediatr 2012; 101:e167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunkel J, de Vries LS, Jongmans M, et al. Outcome of Preterm Infants With Postnatal Cytomegalovirus Infection. Pediatrics 2018; 141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brecht KF, Goelz R, Bevot A, et al. Postnatal human cytomegalovirus infection in preterm infants has long-term neuropsychological sequelae. J Pediatr 2015; 166:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly MS, Benjamin DK, Puopolo KM, et al. Postnatal Cytomegalovirus Infection and the Risk for Bronchopulmonary Dysplasia. JAMA Pediatr 2015; 169:e153785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neuberger P, Hamprecht K, Vochem M, et al. Case-control study of symptoms and neonatal outcome of human milk-transmitted cytomegalovirus infection in premature infants. J Pediatr 2006; 148:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodrich JM, Boeckh M, Bowden R. Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 1994; 19:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovacs A, Schluchter M, Easley K, et al. Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 1999; 341:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunkel J, Wolfs TF, Nijman J, et al. Urine is superior to saliva when screening for postnatal CMV infections in preterm infants. J Clin Virol 2014; 61:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wattles BA, Kim AJ, Cheerva AC, et al. Cytomegalovirus Treatment in Pediatric Hematopoietic Stem Cell Transplant Patients. J Pediatr Hematol Oncol 2017; 39:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu JL, Ma HY, Lu CY, et al. Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients. J Microbiol Immunol Infect 2017; 50:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sedky M, Mekki Y, Mialou V, et al. Cytomegalovirus infection in pediatric allogenic hematopoietic stem cell transplantation. A single center experience. Pediatr Hematol Oncol 2014; 31:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bordon V, Bravo S, Van Renterghem L, et al. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease. Transpl Infect Dis 2008; 10:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doan TT, Phung TT, Pham HV, et al. Effect of ganciclovir for the treatment of severe cytomegalovirus-associated pneumonia in children without a specific immunocompromised state. BMC Infect Dis 2013; 13:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goussard P, Kling S, Gie RP, et al. CMV pneumonia in HIV-infected ventilated infants. Pediatr Pulmonol 2010; 45:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodson EM, Ladhani M, Webster AC, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013; :CD003774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crumpacker CS. Ganciclovir. N Engl J Med 1996; 335:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asberg A, Rollag H, Hartmann A. Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients. Expert Opin Pharmacother 2010; 11:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindemann PC, Foshaugen I, Lindemann R. Characteristics of breast milk and serology of women donating breast milk to a milk bank. Arch Dis Child Fetal Neonatal Ed 2004; 89:F440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paya CV. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin Infect Dis 2001; 32:596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plotkin SA. Vaccination against cytomegalovirus, the changeling demon. Pediatr Infect Dis J 1999; 18:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pass RF, Duliegè AM, Boppana S, et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999; 180:970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009; 360:1191.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5965 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Harrison GJ. Cytomegalovirus. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 8th ed, Cherry JD, Harrison GJ, Kaplan SL, Steinbach W, Hotez P, et al (Eds), Elsevier Saunders, 2019. p.1429.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Mocarski ES. Cytomegaloviruses and their replication. In: Fields Virology, 3rd ed, Fields B, Knipe D, Howley P (Eds), Lippincott-Raven, Philadelphia 1996. Vol 2, p.2447.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11376060" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Characterization of human cytomegalovirus strains by analysis of short tandem repeat polymorphisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32068854" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Cytomegalovirus (CMV) Shedding in French Day-Care Centers: A Nationwide Study of Epidemiology, Risk Factors, Centers' Practices, and Parents' Awareness of CMV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1645882" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Infectious Diseases Society of America and Centers for Disease Control. Summary of a workshop on surveillance for congenital cytomegalovirus disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3036963" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Nosocomial cytomegalovirus infections within two hospitals caring for infants and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23713111" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Breast milk-acquired cytomegalovirus infection and disease in VLBW and premature infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11229670" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11712092" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Cytomegalovirus infection of extremely low-birth weight infants via breast milk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25277116" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Predictors of severity for postnatal cytomegalovirus infection in preterm infants and implications for treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25243446" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Blood transfusion and breast milk transmission of cytomegalovirus in very low-birth-weight infants: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24247027" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : High rate of symptomatic cytomegalovirus infection in extremely low gestational age preterm infants of 22-24 weeks' gestation after transmission via breast milk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27313267" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Incidence, Risk Factors, and Morbidity of Acquired Postnatal Cytomegalovirus Infection Among Preterm Infants Fed Maternal Milk in a Highly Seropositive Population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31326381" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The role of breast-feeding in cytomegalovirus transmission and hematopoietic stem cell transplant outcomes in infants with severe combined immunodeficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26996725" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cytomegalovirus Meningitis in an Infant with Severe Combined Immunodeficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2835741" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Cytomegalovirus transmission among children in day care, their mothers and caretakers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2552316" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Cytomegalovirus and child day care. Evidence for an increased infection rate among day-care workers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7756493" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8394857" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Maternal age and congenital cytomegalovirus infection: screening of two diverse newborn populations, 1980-1990.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28081328" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Cytomegalovirus hepatitis in 49 pediatric patients with normal immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28081328" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Cytomegalovirus hepatitis in 49 pediatric patients with normal immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24144715" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Asymptomatic DNAemia heralds CMV-associated NEC: case report, review, and rationale for preemption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15071286" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Postnatally acquired cytomegalovirus infection via breast milk: effects on hearing and development in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23603882" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Long-term cognitive and neurological outcome of preterm infants with postnatally acquired CMV infection through breast milk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22111513" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Long-term outcome in preterm children with human cytomegalovirus infection transmitted via breast milk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29330315" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Outcome of Preterm Infants With Postnatal Cytomegalovirus Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25466679" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Postnatal human cytomegalovirus infection in preterm infants has long-term neuropsychological sequelae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26642118" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Postnatal Cytomegalovirus Infection and the Risk for Bronchopulmonary Dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16615961" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Case-control study of symptoms and neonatal outcome of human milk-transmitted cytomegalovirus infection in premature infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7986901" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Strategies for the prevention of cytomegalovirus disease after marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10395631" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24986439" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Urine is superior to saliva when screening for postnatal CMV infections in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23896556" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28060118" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Cytomegalovirus Treatment in Pediatric Hematopoietic Stem Cell Transplant Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26346369" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24308761" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Cytomegalovirus infection in pediatric allogenic hematopoietic stem cell transplantation. A single center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17511814" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24010978" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Effect of ganciclovir for the treatment of severe cytomegalovirus-associated pneumonia in children without a specific immunocompromised state.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20575098" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : CMV pneumonia in HIV-infected ventilated infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23450543" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8786764" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Ganciclovir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20367273" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28291720" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15321966" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Characteristics of breast milk and serology of women donating breast milk to a milk bank.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11181123" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10223683" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Vaccination against cytomegalovirus, the changeling demon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10479120" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19297572" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Vaccine prevention of maternal cytomegalovirus infection.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
